uri,title,text,type,authors,tags
http://files.interact.technology/J000523/Abstracts/001_Hogg.pdf,Abstract 1,A new level of control of thrombosis,Plenary 3,Phil Hogg,Barry Firkin Oration
http://files.interact.technology/J000523/Abstracts/002_Wood.pdf,Abstract 2,Karl Landsteiner was on to something,Plenary 3,Erica Wood,Ruth Sanger Oration
http://files.interact.technology/J000523/Abstracts/003_Iland.pdf,Abstract 3,"Curing acute promyelocytic leukaemia - blunderbuss, vitamins, and a poison chaser",Plenary 3,Harry Iland,Carl de Gruchy Oration
http://files.interact.technology/J000523/Abstracts/004_Crighton.pdf,Abstract 4,Use of ferric carboxymaltose in children,Meeting Room 212 & 213,Gemma Crighton,ANZSBT Presidential Symposium
http://files.interact.technology/J000523/Abstracts/005_Flores.pdf,Abstract 5,Improving blood management in obstetrics: a practice improvement partnership,Meeting Room 212 & 213,Cindy Flores,ANZSBT Presidential Symposium
http://files.interact.technology/J000523/Abstracts/006_Dean.pdf,Abstract 6,Development of laboratory assays for multiple parallel assessments of recipient immune responses for use in clinical studies of transfusion outcomes,Meeting Room 212 & 213,Melinda Dean,ANZSBT Presidential Symposium
http://files.interact.technology/J000523/Abstracts/007_McQuilten.pdf,Abstract 7,Epidemiology and outcomes of major obstetric haemorrhage requiring massive transfusion in Australia and New Zealand: Results from the Australasian Maternity Outcomes Surveillance System (AMOSS),Meeting Room 212 & 213,Zoe McQuilten,ANZSBT Presidential Symposium
http://files.interact.technology/J000523/Abstracts/008_Hyland.pdf,Abstract 8,Non Invasive Prenatal Testing (NIPT) for fetal RHD in twin pregnancies,Meeting Room 212 & 213,Catherine Hyland,ANZSBT Presidential Symposium
http://files.interact.technology/J000523/Abstracts/009_Mithraprabhu.pdf,Abstract 9,Circulating free tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in multiple myeloma patients,Plenary 3,Durga Mithraprabhu,Combined HSANZ / ASTH Presidential Symposium
http://files.interact.technology/J000523/Abstracts/010_Dyer.pdf,Abstract 10,The occupational and financial impact of Blood and Marrow Transplantation (BMT) on long-term survivors of BMT in NSW,Plenary 3,Gemma Dyer,Combined HSANZ / ASTH Presidential Symposium
http://files.interact.technology/J000523/Abstracts/011_Kalff.pdf,Abstract 11,ROAR: A Phase Ib trial of oral azacitidine in combination with lenalidomide and dexamethasone (Rd) for patients with relapsed and/or refractory (R/R) multiple myeloma who have failed a prior lenalidomide-containing regimen,Plenary 3,Anna Kalff,Combined HSANZ / ASTH Presidential Symposium
http://files.interact.technology/J000523/Abstracts/012_Asari.pdf,Abstract 12,Point mutations in TKI-resistant Ph-like acute lymphoblastic leukaemia via In vitro modelling: - implications for targeted therapeutic approaches,Plenary 3,Kartini Asari,Combined HSANZ / ASTH Presidential Symposium
http://files.interact.technology/J000523/Abstracts/013_Rabbolini.pdf,Abstract 13,Platelet development and bleeding phenotype is altered with mutation in different zinc finger domains of the GFI1B transcription factor,Meeting Room 219,David Rabbolini,Combined HSANZ / ASTH Presidential Symposium
http://files.interact.technology/J000523/Abstracts/014_Tay.pdf,Abstract 14,Validation of plasma miR-494-3p and miR-365a-3p expression levels as indicators of thrombotic risk,Meeting Room 219,Jasmine Tay,Combined HSANZ / ASTH Presidential Symposium
http://files.interact.technology/J000523/Abstracts/015_Spencer.pdf,Abstract 15,Biology of multiple myeloma: Genetics and epigenetics,Plenary 3,Andrew Spencer,HSANZ Symposium: Myeloma - the science and therapeutic update
http://files.interact.technology/J000523/Abstracts/016_Facon.pdf,Abstract 16,Optimal treatment in de novo and first relapse myeloma,Plenary 3,Thierry Facon,HSANZ Symposium: Myeloma - the science and therapeutic update
http://files.interact.technology/J000523/Abstracts/017_Kurtin.pdf,Abstract 17,LIVING with Cancer:  From the lens of a caregiver,Plenary 3,Sandra Kurtin,HSANZ & Nurses Symposium Survivorship
http://files.interact.technology/J000523/Abstracts/018_Avery.pdf,Abstract 18,Optimising survivorship - The physicians perspective,Plenary 3,Sandra Kurtin,HSANZ & Nurses Symposium Survivorship
http://files.interact.technology/J000523/Abstracts/019_Green.pdf,Abstract 19,The myeloproliferative neoplasms - JAK/STAT signalling and stem cell subversion ,Plenary 3,Tony Green,HSANZ/EHA Symposium: Myeloid disorders
http://files.interact.technology/J000523/Abstracts/020_Dick.pdf,Abstract 20,Clinical relevance of leukemia stem cells in AML,Plenary 3,John Dick,HSANZ/EHA Symposium: Myeloid disorders
http://files.interact.technology/J000523/Abstracts/021_McLintock.pdf,Abstract 21,Thrombocytopenia in pregnancy,Plenary 3,Claire McLintock,"COMBINED SYMPOSIUM (HSANZ, ANZSBT, ASTH & Nurses): Haematological diseases in pregnancy"
http://files.interact.technology/J000511/unavailable.pdf,Abstract 22,Blood Cancer & Pregnancy - Practical management,Plenary 3,Anne Hamilton,"COMBINED SYMPOSIUM (HSANZ, ANZSBT, ASTH & Nurses): Haematological diseases in pregnancy"
http://files.interact.technology/J000511/unavailable.pdf,Abstract 23,Alloummunisation - what's new?,Plenary 3,Helen Savoia,"COMBINED SYMPOSIUM (HSANZ, ANZSBT, ASTH & Nurses): Haematological diseases in pregnancy"
http://files.interact.technology/J000523/Abstracts/024_Yeh.pdf,Abstract 24,Circulating tumour DNA reflects overall disease burden and clonal evolution in chronic lymphocytic leukemia.,Plenary 3,Paul Yeh,HSANZ Early Career Symposium
http://files.interact.technology/J000523/Abstracts/025_Henden.pdf,Abstract 25,Interferon Lambda  is a Critical Cytoprotectant in Bone Marrow Transplantation,Plenary 3,Andrea Henden,HSANZ Early Career Symposium
http://files.interact.technology/J000523/Abstracts/026_Anderson.pdf,Abstract 26,BCL2 selective inhibition with venetoclax induces apoptosis in high risk del(17p) and TP53-defective CLL in vitro and in patients leading to durable responses,Plenary 3,Mary-Ann Anderson,HSANZ Early Career Symposium
http://files.interact.technology/J000523/Abstracts/027_Hsu.pdf,Abstract 27,Therapeutic blood dendritic cell vaccination for acute myeloid leukaemia,Plenary 3,Jennifer Hsu,HSANZ Early Career Symposium
http://files.interact.technology/J000523/Abstracts/028_Yannakou.pdf,Abstract 28,Germline variant detection by next generation sequencing in routine tumour sample analysis - mountain or molehill?,Plenary 3,Costas Yannakou,HSANZ Early Career Symposium
http://files.interact.technology/J000523/Abstracts/029_Low.pdf,Abstract 29,Identifying downstream targets of IRF4 for therapeutic targeting in myeloma,Plenary 3,Michael Low,HSANZ Early Career Symposium
http://files.interact.technology/J000523/Abstracts/030_Friedberg.pdf,Abstract 30,Novel agents - who needs them?,Plenary 3,Jonathan W. Friedberg,HSANZ Symposium: Indolent lymphoma
http://files.interact.technology/J000523/Abstracts/031_Treon.pdf,Abstract 31,Genomic based treatment advances in Waldenstrom's Macroglobulinemia,Plenary 3,Steven Treon,HSANZ Symposium: Indolent lymphoma
http://files.interact.technology/J000523/Abstracts/032_Renwick.pdf,Abstract 32,A frailty scale predicts outcomes in transplant-ineligible patients with newly-diagnosed Multiple Myeloma (NDMM) Treated in the FIRST Trial with continuous Lenalidomide plus low-dose Dexamethasone (Rd),Plenary 3,William Renwick,HSANZ Free Communications 1: Myeloma Clinical I
http://files.interact.technology/J000523/Abstracts/033_Scott.pdf,Abstract 33,‘Real-world’ Australian experience of pomalidomide for relapsed/refractory myeloma,Plenary 3,Ashleigh Scott,HSANZ Free Communications 1: Myeloma Clinical I
http://files.interact.technology/J000523/Abstracts/033_Scott.pdf,Abstract 34,Myeloma outcomes in New Zealand: Increasing regional variation,Plenary 3,David Simpson,HSANZ Free Communications 1: Myeloma Clinical I
http://files.interact.technology/J000523/Abstracts/035_Wong%20Doo.pdf,Abstract 35,Early autologous stem cell transplant associated with improved overall survival in multiple myeloma: findings from a population based study,Plenary 3,Nicole Wong Doo,HSANZ Free Communications 1: Myeloma Clinical I
http://files.interact.technology/J000523/Abstracts/036_Taylor.pdf,Abstract 36,Transplantation in FLT-3-ITD+ AML with normal karyotype is associated with improved overall survival,Meeting Room 217,Emma Taylor,HSANZ Free Communications 2: Bone Marrow Transplantation
http://files.interact.technology/J000523/Abstracts/037_Wong.pdf,Abstract 37,The prognostic impact of early donor chimerism after allogeneic stem cell transplantation is dependent on disease risk index,Meeting Room 217,Eric Wong,HSANZ Free Communications 2: Bone Marrow Transplantation
http://files.interact.technology/J000523/Abstracts/038_Wright.pdf,Abstract 38,"Biopsychosocial outcomes of Victorian Allogeneic Stem Cell Transplant (alloSCT) Late Effects (LE) Program: Metabolic Syndrome (MetS), Quality of Life  (QOL) & returning to work",Meeting Room 217,Tricia Wright,HSANZ Free Communications 2: Bone Marrow Transplantation
http://files.interact.technology/J000523/Abstracts/039_Birchley.pdf,Abstract 39,"Early acute kidney injury post allogeneic stem cell transplant is associated with increased risk of GVHD, higher mortality and reduced survival",Meeting Room 217,Andrew Birchley,HSANZ Free Communications 2: Bone Marrow Transplantation
http://files.interact.technology/J000523/Abstracts/040_Bennett.pdf,Abstract 40,Inhibition of glucosylceramide synthase induces apoptotic cell death in multiple myeloma cells,Meeting Room 218,Melissa Bennett,HSANZ Free Communications 3: Myeloma Biology
http://files.interact.technology/J000523/Abstracts/041_Nair.pdf,Abstract 41,Application of EuroFlow for minimal residual disease detection of multiple myeloma following tandem autologous-NMA allogeneic stem cell transplantation,Meeting Room 218,Anish Nair,HSANZ Free Communications 3: Myeloma Biology
http://files.interact.technology/J000523/Abstracts/042_Reale.pdf,Abstract 42,TOP2A a new predictive marker of response to Carfilzomib in multiple myeloma,Meeting Room 218,Antonia Reale,HSANZ Free Communications 3: Myeloma Biology
http://files.interact.technology/J000523/Abstracts/043_Savvidou.pdf,Abstract 43,Overcoming innate resistance to a new beta-catenin inhibitor by manipulating the autophagic pathway in Multiple Myeloma,Meeting Room 218,Ioanna Savvidou,HSANZ Free Communications 3: Myeloma Biology
http://files.interact.technology/J000523/Abstracts/044_Forsyth.pdf,Abstract 44,The delayed diagnosis of Philadelphia negative Myeloproliferative Neoplasms (MPN) is common and results in a high incidence of potentially preventable thrombotic complications,Meeting Room 211,Cecily Forsyth,HSANZ Free Communications 4: Myeloproliferative Disorders
http://files.interact.technology/J000523/Abstracts/045_Hughes.pdf,Abstract 45,Immune responses in Chronic Myeloid Leukaemia patients following cessation of Tyrosine Kinase Inhibitor,Meeting Room 211,Amy Hughes,HSANZ Free Communications 4: Myeloproliferative Disorders
http://files.interact.technology/J000523/Abstracts/046_Pagani.pdf,Abstract 46,Mitochondrial DNA mutations at diagnosis are linked to response in TKI treated chronic myeloid leukaemia patients,Meeting Room 211,Ilaria stefanie Pagani,HSANZ Free Communications 4: Myeloproliferative Disorders
http://files.interact.technology/J000523/Abstracts/047_Ryland.pdf,Abstract 47,Targeted amplicon sequencing combined with selected extended sequencing efficiently establishes diagnoses in conventional and triple-negative BCR-ABL negative myeloproliferative neoplasms in the molecular diagnostic laboratory,Meeting Room 211,Georgie Ryland,HSANZ Free Communications 4: Myeloproliferative Disorders
http://files.interact.technology/J000511/unavailable.pdf,Abstract 48,Biology and therapy of Waldenstrom’s Macroglobulinemia,Meeting Room 217,Steven Treon,"HSANZ Masterclass: Waldenstroms (Steven Treon)

"
http://files.interact.technology/J000511/unavailable.pdf,Abstract 49,Clinician scientists – bridging the MPN divide,Meeting Room 218,Tony Green,HSANZ Masterclass: MPN (Anthony Green)
http://files.interact.technology/J000523/Abstracts/050_Shortt.pdf,Abstract 50,Single hit lymphoma,Plenary 3,Jake Shortt,"HSANZ Symposium: Aggressive lymphoma

"
http://files.interact.technology/J000523/Abstracts/051_Trotman.pdf,Abstract 51,Ann Arbor staging vs. total metabolic tumour volume. Time for a change?,Plenary 3,Judith Trotman,"HSANZ Symposium: Aggressive lymphoma

"
http://files.interact.technology/J000523/Abstracts/052_Hertzberg.pdf,Abstract 52,Hodgkin lymphoma gone bad,Plenary 3,Mark Hertzberg,"HSANZ Symposium: Aggressive lymphoma

"
http://files.interact.technology/J000523/Abstracts/053_Juneja.pdf,Abstract 53,The 2016 revision of the WHO classification of myeloid neoplasms & acute leukaemia,Meeting Room 216,Surender Juneja,Lab Haematology Symposium 1: MDS and AML
http://files.interact.technology/J000523/Abstracts/053_Juneja.pdf,Abstract 54,Update on molecular diagnostics of AML & MDS,Meeting Room 216,Piers Blombery,Lab Haematology Symposium 1: MDS and AML
http://files.interact.technology/J000511/unavailable.pdf,Abstract 55,Novel therapies in thalassaemia,Plenary 3,Vip Viprakasit,HSANZ & ANZSBT: Haemoglobinopathies
http://files.interact.technology/J000523/Abstracts/056_Ware.pdf,Abstract 56,Global strategies for sickle cell disease,Plenary 3,Russell Ware,HSANZ & ANZSBT: Haemoglobinopathies
http://files.interact.technology/J000523/Abstracts/056_Ware.pdf,Abstract 57,Towards novel therapies for the hemoglobinopathies,Plenary 3,Stephen Jane,HSANZ & ANZSBT: Haemoglobinopathies
http://files.interact.technology/J000523/Abstracts/058_Young.pdf,Abstract 58,Aplastic anemia: Treating the hematopoietic stem cell,Plenary 3,Neil Young,HSANZ Symposium: Aplastic Anaemia
http://files.interact.technology/J000523/Abstracts/059_Firkin.pdf,Abstract 59,Objectives and progress of the Australian Aplastic Anaemia Registry,Plenary 3,Frank Firkin,HSANZ Symposium: Aplastic Anaemia
http://files.interact.technology/J000523/Abstracts/060_Lade.pdf,Abstract 60,Update on 2016 WHO classification of lymphoid neoplasms,Meeting Room 216,Stephen Lade,Lab Haematology Symposium 2
http://files.interact.technology/J000523/Abstracts/061_Sartor.pdf,Abstract 61,A review of the RCPA EQA program for paroxysmal nocturnal haemoglobinuria,Meeting Room 216,Mary Sartor,Lab Haematology Symposium 2
http://files.interact.technology/J000523/Abstracts/062_Huang.pdf,Abstract 62,The science behind BcL2 inhibition,Plenary 3,David Huang,HSANZ Symposium: Bcl2 inhibition - The science and clinical impact
http://files.interact.technology/J000523/Abstracts/063_Anderson.pdf,Abstract 63,Bcl2 inhibition in lymphoproliferative disease,Plenary 3,Mary Ann Anderson,HSANZ Symposium: Bcl2 inhibition - The science and clinical impact
http://files.interact.technology/J000523/Abstracts/064_Wei.pdf,Abstract 64,Therapeutic progress in targeting apoptosis pathways in AML,Plenary 3,Andrew Wei,HSANZ Symposium: Bcl2 inhibition - The science and clinical impact
http://files.interact.technology/J000511/unavailable.pdf,Abstract 65,Precision approach to Follicular Lymphoma,Meeting Room 216,Jonathan W. Friedberg,HSANZ Masterclass: Lymphoma (Jonathan Friedberg)
http://files.interact.technology/J000511/unavailable.pdf,Abstract 66,Myeloma: Front line therapy in transplant ineligible patients,Meeting Room 217,Thierry Facon,HSANZ Masterclass: Myeloma (Theirry Facon)
http://files.interact.technology/J000523/Abstracts/067_Young.pdf,Abstract 67,Constitutional bone marrow failure syndromes manifesting in adults,Meeting Room 218,Neal Young,HSANZ Masterclass: Bone marrow failure (Neal Young)
http://files.interact.technology/J000523/Abstracts/068_Wong.pdf,Abstract 68,99m Technetium-hydroxy-diphosphate Tracer (99mTcHDP) bone scintigraphy: A non-invasive diagnostic tool for cardiac amyloidosis,Plenary 3,Caroline Wong,HSANZ Free Communications 5: Myeloma Clinical II
http://files.interact.technology/J000523/Abstracts/069_Bergin.pdf,Abstract 69,Rates of upfront autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM):  a report from the MRDR on behalf of the MRDR steering committee,Plenary 3,Krystal Bergin,HSANZ Free Communications 5: Myeloma Clinical II
http://files.interact.technology/J000523/Abstracts/070_Gibbs.pdf,Abstract 70,"Monoclonal antibodies in systemic AL amyloidosis - when it rains, in pours",Plenary 3,Simon Gibbs,HSANZ Free Communications 5: Myeloma Clinical II
http://files.interact.technology/J000523/Abstracts/071_Kalff.pdf,Abstract 71,A 2-stage phase II study of panobinostat consolidation in Multiple Myeloma (MM) patients with < CR Following High-Dose Chemotherapy (HDT) conditioned Autologous Stem Cell Transplantation (ASCT) as part of first line therapy,Plenary 3,Anna Kalff,HSANZ Free Communications 5: Myeloma Clinical II
http://files.interact.technology/J000523/Abstracts/072_Liedtke.pdf,Abstract 72,NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study,Plenary 3,Michaela liedtke,HSANZ Free Communications 5: Myeloma Clinical II
http://files.interact.technology/J000523/Abstracts/073_Moore.pdf,Abstract 73,Renal impairment in myeloma: a comparison of characteristics and outcomes in patients with and without renal impairment in the Australia and New Zealand myeloma and related diseases registry,Plenary 3,Elizabeth Moore,HSANZ Free Communications 5: Myeloma Clinical II
http://files.interact.technologyJ000523/Abstracts/074_Blombery.pdf,Abstract 74,Genomic characterisation of breast implant-associated anaplastic large cell lymphoma reveals a high incidence of activating JAK1/STAT3 mutations and identifies predisposing germline variants,Meeting Room 216,Piers Blombery,HSANZ Free Communications 6: Lymphoma
http://files.interact.technology/J000523/Abstracts/075_Falconer.pdf,Abstract 75,The frequency of incidental malignancies detected by PET/CT scans in patients with lymphoma and the associated clinical implications,Meeting Room 216,Janlyn Falconer,HSANZ Free Communications 6: Lymphoma
http://files.interact.technology/J000523/Abstracts/076_Ratnasingam.pdf,Abstract 76,Improved survival of older patients with Mantle Cell Lymphoma (MCL) with cytarabine-based immunochemotherapy,Meeting Room 216,Sumita Ratnasingam,HSANZ Free Communications 6: Lymphoma
http://files.interact.technology/J000523/Abstracts/077_Tam.pdf,Abstract 77,Frequent achievement of complete remissions in patients with relapsed / refractory mantle cell lymphoma treated with the combination of Ibrutinib and Venetoclax (ABT-199): results from the ongoing Australian Phase 2 AIM study,Meeting Room 216,Constantine Tam,HSANZ Free Communications 6: Lymphoma
http://files.interact.technology/J000523/Abstracts/078_Tang.pdf,Abstract 78,Primary central nervous system lymphoma: a tertiary institution experience over the last decade,Meeting Room 216,Catherine Tang,HSANZ Free Communications 6: Lymphoma
http://files.interact.technology/J000523/Abstracts/079_van%20der%20Weyden.pdf,Abstract 79,A retrospective review of treatment outcomes in patients treated for peripheral T cell Lymphoma (PTCL) at the Peter MacCallum Cancer Centre (PMCC) between 1999 and 2015,Meeting Room 216,Carrie Van Der Weyden,HSANZ Free Communications 6: Lymphoma
http://files.interact.technology/J000523/Abstracts/080_Chunilal.pdf,Abstract 80,Safety of RAPid INJECTion of undiluted ferric carboxymaltose to patients with iron deficiency anaemia (RAPINJECT),Meeting Room 217,Sanjeev Chunilal,HSANZ Free Communications 7: Non-Malignant
http://files.interact.technology/J000523/Abstracts/081_Ho.pdf,Abstract 81,"Prevalence of cardiac and hepatic siderosis in Australian patients with transfusion-dependent anaemias or non-transfusion-dependent thalassaemia, as assessed by MRI (the TIMES Study)",Meeting Room 217,P. Joy Ho,HSANZ Free Communications 7: Non-Malignant
http://files.interact.technology/J000523/Abstracts/082_Hsu.pdf,Abstract 82,"An observational, non-interventional, multicentre,  registry of patients with atypical haemolytic uraemic syndrome (aHUS): A review of the baseline characteristics of patients treated with eculizumab in the Australian cohort",Meeting Room 217,Danny Hsu,HSANZ Free Communications 7: Non-Malignant
http://files.interact.technology/J000523/Abstracts/083_Khalafallah.pdf,Abstract 83,Treatment of iron deficiency anaemia of late pregnancy with a single intravenous ferric carboxymaltose or iron polymaltose infusion versus daily oral iron sulphate (TIDAL): a prospective randomised controlled trial,Meeting Room 217,Alhossain Khalafallah,HSANZ Free Communications 7: Non-Malignant
http://files.interact.technology/J000523/Abstracts/084_Kivivali.pdf,Abstract 84,Emerging insights into efficacy of aplastic anaemia management practices from the Australian Aplastic Anaemia Registry,Meeting Room 217,Leah Kivivali,HSANZ Free Communications 7: Non-Malignant
http://files.interact.technology/J000523/Abstracts/085_Jones.pdf,Abstract 85,Novel next generation sequencing based minimal residual disease testing utilising non-conventional molecular targets in acute myeloid leukaemia,Meeting Room 220,Kate Jones,HSANZ Free Communications 8: Acute Myeloid Leukaemia & Myelodysplasia
http://files.interact.technology/J000523/Abstracts/086_Sillar.pdf,Abstract 86,Reactive oxygen species promote leukaemogenesis via altered redox signalling pathways in FLT3-ITD+ acute myeloid leukaemia,Meeting Room 220,Jonathan Sillar,HSANZ Free Communications 8: Acute Myeloid Leukaemia & Myelodysplasia
http://files.interact.technology/J000523/Abstracts/087_Vu.pdf,Abstract 87,miR-10a as a predictive biomarker in Normal Karyotype (NK) Acute Myeloid Leukaemia (AML),Meeting Room 220,Thi Thanh Vu,HSANZ Free Communications 8: Acute Myeloid Leukaemia & Myelodysplasia
http://files.interact.technology/J000523/Abstracts/088_Jeffrey.pdf,Abstract 88,Low-dose Cytarabine and Thioguanine Based Metronomic Chemotherapy (STIMULus) as salvage in elderly patients with relapsed or refractory acute myeloid leukaemia (AML),Meeting Room 220,Anthony Jeffrey,HSANZ Free Communications 8: Acute Myeloid Leukaemia & Myelodysplasia
http://files.interact.technology/J000523/Abstracts/089_Schwarer.pdf,Abstract 89,A single high-dose cytarabine (HiDAC) during induction-consolidation may not be adequate for patients with a new diagnosis of acute myeloid leukaemia (AML) not planned for allogeneic haematopoietic stem cell transplantation (alloHSCT) in 1st complete Remission (CR1),Meeting Room 220,Anthony Schwarer,HSANZ Free Communications 8: Acute Myeloid Leukaemia & Myelodysplasia
http://files.interact.technology/J000523/Abstracts/090_Watts.pdf,Abstract 90,Determining mechanisms of resistance to Azacitidine (Aza) in Myelodysplastic (MDS) syndromes and Acute Myeloid Leukaemia (AML) using an in-vitro model,Meeting Room 220,Sophie Watts,HSANZ Free Communications 8: Acute Myeloid Leukaemia & Myelodysplasia
http://files.interact.technology/J000523/Abstracts/091_Spitalnik.pdf,Abstract 91,"Stored RBC transfusions: Iron, inflammation, immunity, infection",Meeting Room 212 & 213,Steven Spitalnik,ANZSBT & HSANZ: RBC
http://files.interact.technology/J000523/Abstracts/093_Dzik.pdf,Abstract 92,Kruppeling erythropoiesis,Meeting Room 212 & 213,Andrew Perkins,ANZSBT & HSANZ: RBC
http://files.interact.technology/J000523/Abstracts/094_Esmon.pdf,Abstract 93,The air they breathe,Meeting Room 212 & 213,Walter H. Dzik,ANZSBT & HSANZ: RBC
http://files.interact.technology/J000523/Abstracts/095_Cowan.pdf,Abstract 94,"Involvement of the protein C pathway in cancer, kidney disease and malaria",Meeting Room 219,Charles Esmon,ASTH Symposium: Inflammation thrombosis
http://files.interact.technology/J000523/Abstracts/096_Weitz.pdf,Abstract 95,Cross-species incompatibility of thrombomodulin: Implications and solutions for xenotransplantation,Meeting Room 219,Peter Cowan,ASTH Symposium: Inflammation thrombosis
http://files.interact.technology/J000523/Abstracts/097_McFadyen.pdf,Abstract 96,Valves thrombosis,Meeting Room 219,Jeffrey Weitz,ASTH Symposium: Contact pathways
http://files.interact.technology/J000523/Abstracts/098_Roxby.pdf,Abstract 97,Being in the right place at the right time: Targeted anti-thrombotic approaches,Meeting Room 219,James McFadyen,ASTH Symposium: Contact pathways
http://files.interact.technology/J000523/Abstracts/099_Nesbitt.pdf,Abstract 98,Thromboelastography,Meeting Room 219,David Roxby,ASTH Symposium: Diagnostic tools
http://files.interact.technology/J000523/Abstracts/100_Andrews.pdf,Abstract 99,A shear based microfluidic device to monitor platelet function: Application to von Willebrand disease screening,Meeting Room 219,Warwick Nesbitt,ASTH Symposium: Diagnostic tools
http://files.interact.technology/J000523/Abstracts/101_Morel-Kopp.pdf,Abstract 100,Soluble platelet proteins that help evaluate thrombocytopenia and stratify bleeding risk,Meeting Room 219,Robert Andrews,ASTH Symposium: Diagnostic tools
http://files.interact.technology/J000523/Abstracts/102_Duncan.pdf,Abstract 101,Identification of a new dysfunctional platelet P2Y12 receptor variant in a family with bleeding history,Meeting Room 219,Marie-Christine Morel-Kopp,ASTH Free Communications 1
http://files.interact.technology/J000523/Abstracts/103_Tiao.pdf,Abstract 102,Establishment of a diagnostic algorithm for Heparin induced thrombocytopenia that includes a rapid chemiluminescent immunoassay as the initial laboratory test,Meeting Room 219,Elizabeth Duncan,ASTH Free Communications 1
http://files.interact.technology/J000523/Abstracts/104_Chun.pdf,Abstract 103,Improving Microangiopathic Thrombocytopenia(MAT) diagnosis in the Asia-Pacific region by standardisation of the ADAMTS-13 assay,Meeting Room 219,Jim Tiao,ASTH Free Communications 1
http://files.interact.technology/J000523/Abstracts/105_Simonova.pdf,Abstract 104,MYH9 disorders are not uncommon in Australia and New Zealand: results from a platelet next generation sequencing (NGS) project,Meeting Room 219,Yenna Chun,ASTH Free Communications 1
http://files.interact.technology/J000523/Abstracts/106_Ginsborg.pdf,Abstract 105,Point-of-care testing of coagulation during extracorporeal membrane oxygenation in a sheep model,Meeting Room 219,Gabriela Simonova,ASTH Free Communications 1
http://files.interact.technology/J000523/Abstracts/107_Dunkley.pdf,Abstract 106,Diagnostic algorithm in Heparin Induced Thrombotic Thrombocytopenia (HITT): review of serotonin release assay results,Meeting Room 219,Lette Ginsborg,ASTH Free Communications 1
http://files.interact.technology/J000523/Abstracts/108_Rabbolini.pdf,Abstract 107,Rare hereditary bleeding disorders,Meeting Room 219,Scott Dunkley,ASTH: Bleeding disorders
http://files.interact.technology/J000523/Abstracts/109_Tran.pdf,Abstract 108,Genetic testing in the investigation of patients with suspected inherited thrombocytopenia,Meeting Room 219,David Rabbolini,ASTH: Bleeding disorders
http://files.interact.technology/J000523/Abstracts/110_Medcalf.pdf,Abstract 109,Acquired haemophilia,Meeting Room 219,Huyen Tran,ASTH: Bleeding disorders
http://files.interact.technology/J000523/Abstracts/111_Myles.pdf,Abstract 110,Brain trauma and the role of anti-fibrinolytic agents,Meeting Room 219,Robert Medcalf,ASTH Symposium: Antifibrinolysis (TA) in clinical
http://files.interact.technology/J000523/Abstracts/112_Campbell.pdf,Abstract 111,Tranexamic acid in cardiac surgery,Meeting Room 219,Paul Myles,ASTH Symposium: Antifibrinolysis (TA) in clinical
http://files.interact.technology/J000523/Abstracts/113_Brighton.pdf,Abstract 112,Thrombolysis vs thrombectomy in stroke,Meeting Room 219,Bruce Campbell,ASTH Symposium: Antifibrinolysis (TA) in clinical
http://files.interact.technology/J000523/Abstracts/114_Yuen.pdf,Abstract 113,Residual vein thrombus does not predict for recurrent vein thrombosis in the ASPIRE study,Meeting Room 219,Timothy Brighton,"ASTH Free Communications 2

"
http://files.interact.technology/J000523/Abstracts/115_Barnes.pdf,Abstract 114,Venous Thromboembolism (VTE) in patients with primary central nervous system lymphoma (PCNSL) receiving R-MPV,Meeting Room 219,Hiu Lam Agnes Yuen,"ASTH Free Communications 2

"
http://files.interact.technology/J000523/Abstracts/116_McRae.pdf,Abstract 115,Phase 3 trial results demonstrating efficacy and safety of rIX-FP in children with Haemophilia B,Meeting Room 219,Christopher Barnes,"ASTH Free Communications 2

"
http://files.interact.technology/J000523/Abstracts/117_McCaughan.pdf,Abstract 116,Current practice regarding prophylaxis in patients with moderate and severe haemophilia A in Australia,Meeting Room 219,Simon McRae,"ASTH Free Communications 2

"
http://files.interact.technology/J000523/Abstracts/118_Baker.pdf,Abstract 117,Choice of anticoagulation in veno-thromboembolic disease in obese patients,Meeting Room 219,Georgia McCaughan,"ASTH Free Communications 2

"
http://files.interact.technology/J000523/Abstracts/119_Williams.pdf,Abstract 118,Clinical utility of specific DOAC plasma concentration assessments in the ASTH Anticoagulation Reversal and Events Study Collaborative (ARES1),Meeting Room 219,Ross Baker,"ASTH Free Communications 2

"
http://files.interact.technology/J000523/Abstracts/120_McGiffin.pdf,Abstract 119,Pulmonary hypertension: What Haematologists need to know,Meeting Room 219,Trevor Williams,ASTH Symposium: Pulmonary HPT & vascular intervention
http://files.interact.technology/J000523/Abstracts/093_Dzik.pdf,Abstract 120,Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension,Meeting Room 219,David McGiffin,ASTH Symposium: Pulmonary HPT & vascular intervention
http://files.interact.technology/J000511/unavailable.pdf,Abstract 121,Localised intervention,Meeting Room 219,John Vrazas,ASTH Symposium: Pulmonary HPT & vascular intervention
http://files.interact.technology/J000511/unavailable.pdf,Abstract 122,ISTH reversal guidelines,Meeting Room 219,Noel Chan Wan Kai,ASTH Symposium: NOAC reversal
http://files.interact.technology/J000523/Abstracts/123_Weitz.pdf,Abstract 123,Strategies to minimize the risk of bleeding with direct oral anticoagulants,Meeting Room 219,Jeffrey Weitz,ASTH Symposium: NOAC reversal
http://files.interact.technology/J000511/unavailable.pdf,Abstract 124,ARES update,Meeting Room 219,Ross Baker,ASTH Symposium: NOAC reversal
http://files.interact.technology/J000523/Abstracts/125_Hoffmeister.pdf,Abstract 125,AMR (1) – Platelet production,Meeting Room 212 & 213,Karin Hoffmeister,ANZSBT & ASTH Symposium: Platelets
http://files.interact.technology/J000511/unavailable.pdf,Abstract 126,Procoagulant platelets contribute to occlusive thrombus formation and are formed via the Cyclophilin D dependent necrosis pathway,Meeting Room 212 & 213,Vivien Chen,ANZSBT & ASTH Symposium: Platelets
http://files.interact.technology/J000523/Abstracts/127_Josefsson.pdf,Abstract 127,"Apoptotic death prevents the functional decline of platelets in vivo, but apoptosis is not required for the development of the platelet storage lesion",Meeting Room 212 & 213,Emma Josefsson,ANZSBT & ASTH Symposium: Platelets
http://files.interact.technology/J000523/Abstracts/128_McRae.pdf,Abstract 128,Development of Australian guidelines for the treatment of haemophilia,Meeting Room 219,Simon McRae,"ASTH Free Communications 3

"
http://files.interact.technology/J000523/Abstracts/129_Stevens.pdf,Abstract 129,Anticoagulation for Venous Thromboembolism (VTE) and rates of per vaginal bleeding in pre-menopausal women,Meeting Room 219,Hannah Stevens,"ASTH Free Communications 3

"
http://files.interact.technology/J000523/Abstracts/130_Slocombe.pdf,Abstract 130,Venous thromboembolism rates and validation of the Khorana score in diffuse large B-cell lymphoma,Meeting Room 219,Alison Slocombe,"ASTH Free Communications 3

"
http://files.interact.technology/J000523/Abstracts/131_Burchall.pdf,Abstract 131,"Aberrant haemostasis from OCP, but not Metformin use in Polycystic Ovarian Syndrome (PCOS)",Meeting Room 219,Genia Burchall,"ASTH Free Communications 3

"
http://files.interact.technology/J000523/Abstracts/132_Tran.pdf,Abstract 132,The risk of inhibitor development among congenital haemophilia patients who receive factor concentrate replacement via continuous infusion,Meeting Room 219,Huyen Tran,"ASTH Free Communications 3

"
http://files.interact.technology/J000523/Abstracts/133_Joseph.pdf,Abstract 133,Preoperative assessment of bleeding risk – how are we really performing?,Meeting Room 219,Joanne Joseph,"ASTH Free Communications 3

"
http://files.interact.technology/J000523/Abstracts/134_McLintock.pdf,Abstract 134,Obstetric DIC,Meeting Room 219,Claire McLintock,ASTH Symposium: DIC
http://files.interact.technology/J000523/Abstracts/135_Esmon.pdf,Abstract 135,"The protein C pathway and histone participation in DIC, thrombosis, organ failure and death",Meeting Room 219,Charles Esmon,ASTH Symposium: DIC
http://files.interact.technology/J000523/Abstracts/136_Brighton.pdf,Abstract 136,DIC in cancer,Meeting Room 219,Timothy Brighton,ASTH Symposium: DIC
http://files.interact.technology/J000511/unavailable.pdf,Abstract 137,Disaster preparedness and recovery,Meeting Room 212 & 213,Alison McMillan,ANZSBT: Disaster preparedness and recovery
http://files.interact.technology/J000523/Abstracts/138_Waters.pdf,Abstract 138,Disasters I have contributed to,Meeting Room 212 & 213,Neil Waters,ANZSBT: Disaster preparedness and recovery
http://files.interact.technology/J000523/Abstracts/139_Flanagan.pdf,Abstract 139,Reflections on the Christchurch earthquake,Meeting Room 212 & 213,Peter Flanagan,ANZSBT: Disaster preparedness and recovery
http://files.interact.technology/J000523/Abstracts/140_Spitalnik.pdf,Abstract 140,Pathophysiology of Hemolytic Transfusion Reactions,Meeting Room 212 & 213,Steven Spitalnik,ANZSBT: Transfusion reactions
http://files.interact.technology/J000523/Abstracts/141_Luban.pdf,Abstract 141,Paediatric transfusion reactions and alloimmunisation,Meeting Room 212 & 213,Naomi Luban,ANZSBT: Transfusion reactions
http://files.interact.technology/J000523/Abstracts/142_Thornton.pdf,Abstract 142,Investigation of complex Rh antibody problems in pregnancy,Meeting Room 212 & 213,Nicole Thornton,ANZSBT: Pregnancy
http://files.interact.technology/J000511/unavailable.pdf,Abstract 143,Haemoglobinopathy and thalassaemia management in pregnancy,Meeting Room 212 & 213,Giselle Kidson-Gerber,ANZSBT: Pregnancy
http://files.interact.technology/J000523/Abstracts/144_Pennell.pdf,Abstract 144,Single dose Anti-D prophylaxis in pregnancy: is it time to change?,Meeting Room 212 & 213,Craig Pennell,ANZSBT: Pregnancy
http://files.interact.technology/J000523/Abstracts/145_Dzik.pdf,Abstract 145,100 milion RBC transfusions each year…but do they deliver oxygen?,Meeting Room 212 & 213,Walter H. Dzik,ANZSBT: Paediatric  and neonatal transfusion
http://files.interact.technology/J000523/Abstracts/146_Luban.pdf,Abstract 146,Paediatric PBM,Meeting Room 212 & 213,Naomi Luban,ANZSBT: Paediatric  and neonatal transfusion
http://files.interact.technology/J000523/Abstracts/147_Liley.pdf,Abstract 147,Module 6: Neonatal and Paediatric Patient Blood Management,Meeting Room 212 & 213,Helen Liley,ANZSBT: Paediatric  patient blood management
http://files.interact.technology/J000523/Abstracts/148_Crighton.pdf,Abstract 148,International neonatal and paediatric Patient Blood Management guidelines,Meeting Room 212 & 213,Gemma Crighton,ANZSBT: Paediatric  patient blood management
http://files.interact.technology/J000523/Abstracts/149_Thornton.pdf,Abstract 149,The immunohaematology toolbox for solving complex antibody cases,Meeting Room 212 & 213,Nicole Thornton,ANZSBT/ ISBT Academy Session: Resolving tricky issues in the transfusion laboratory
http://files.interact.technology/J000523/Abstracts/150_Rushford.pdf,Abstract 150,Dealing with challenging antibodies,Meeting Room 212 & 213,Kylie Rushford,ANZSBT/ ISBT Academy Session: Resolving tricky issues in the transfusion laboratory
http://files.interact.technology/J000523/Abstracts/151_Oh.pdf,Abstract 151,Antibody soup: Challenging transfusion management issues in thalassaemia major,Meeting Room 212 & 213,Danielle Oh,ANZSBT/ ISBT Academy Session: Resolving tricky issues in the transfusion laboratory
http://files.interact.technology/J000523/Abstracts/152_Dzik.pdf,Abstract 152,How to get your work published in a medical journal,Meeting Room 211,Walter H. Dzik,ANZSBT Masterclass: How to get published in a peer reviewed journal (Sunny Dzik)
http://files.interact.technology/J000523/Abstracts/153_Ruseckaite.pdf,Abstract 153,Risk factors for 30-day mortality in critically bleeding patients requiring massive transfusion within 24 hours of admission to the Intensive Care Unit,Meeting Room 212 & 213,Rasa Ruseckaite,ANZSBT - Free Communications - Clinical
http://files.interact.technology/J000523/Abstracts/154_Swain.pdf,Abstract 154,"Transfusion-Related Acute Lung Injury (TRALI): A review of reported TRALI cases in Queensland, Australia, between 1999 and June 2016",Meeting Room 212 & 213,Fiona Swain,ANZSBT - Free Communications - Clinical
http://files.interact.technology/J000523/Abstracts/155_Higgins.pdf,Abstract 155,"Determining the frequency, costs and outcomes of red blood cell transfusion in hospitalised patients: a pilot study",Meeting Room 212 & 213,Alisa Higgins,ANZSBT - Free Communications - Clinical
http://files.interact.technology/J000523/Abstracts/156_Behan.pdf,Abstract 156,Gastrointestinal bleeding-red blood cell transfusion and patient blood management practice in a metropolitan hospital,Meeting Room 212 & 213,Daniel Behan,ANZSBT - Free Communications - Clinical
http://files.interact.technology/J000523/Abstracts/157_Crighton.pdf,Abstract 157,"The Australian haemoglobinopathy registry: aims, plans and pilot data",Meeting Room 212 & 213,Gemma Crighton,ANZSBT - Free Communications - Clinical
http://files.interact.technology/J000523/Abstracts/158_Fung.pdf,Abstract 158,Preliminary data on cost of IVIg & SCIg treatment in adult Australian patients,Meeting Room 212 & 213,Lin Fung,ANZSBT - Free Communications - Clinical
http://files.interact.technology/J000523/Abstracts/159_Hyland.pdf,Abstract 159,"Can extended genotyping, using a comprehensive and targeted blood group sequencing, assist in resolving complex serology problems in chronic transfused patients?",Meeting Room 217,Catherine Hyland,ANZSBT Free Communications - Laboratory
http://files.interact.technology/J000523/Abstracts/160_Lopez.pdf,Abstract 160,A novel molecular mechanism in RHD caused the deletion of Exon 9 resulting in a partial DEL phenotype,Meeting Room 217,Genghis Lopez,ANZSBT Free Communications - Laboratory
http://files.interact.technology/J000523/Abstracts/161_Wilkes.pdf,Abstract 161,Managing anti-CD38 (Daratumumab) interference with pre-transfusion testing in a||busy hospital transfusion laboratory,Meeting Room 217,Anne-Marie Wilkes,ANZSBT Free Communications - Laboratory
http://files.interact.technology/J000523/Abstracts/162_Badami.pdf,Abstract 162,Platelets in Platelet Additive Solution (PAS) cause fewer allergic reactions compared to platelets in plasma – data from NZBS Haemovigilance and possible mechanisms,Meeting Room 217,Krishna Badami,ANZSBT Free Communications - Laboratory
http://files.interact.technology/J000523/Abstracts/163_Oh.pdf,Abstract 163,The challenges of providing phenotyped matched red cells in contemporary Australian practice,Meeting Room 217,Danielle Oh,ANZSBT Free Communications - Laboratory
http://files.interact.technology/J000523/Abstracts/164_Marks.pdf,Abstract 164,Extending the post-thaw shelf-life of cryoprecipitate,Meeting Room 217,Denese Marks,ANZSBT Free Communications - Laboratory
http://files.interact.technology/J000523/Abstracts/165_Flanagan.pdf,Abstract 165,An update on emerging infections threats to the safety of the blood supply,Meeting Room 212 & 213,Peter Flanagan,ANZSBT - An update on emerging infectious threats
http://files.interact.technology/J000523/Abstracts/166_Buttery.pdf,Abstract 166,What is the role for immunoglobulin products in the era of better vaccinations and new drugs?,Meeting Room 212 & 213,Jim Buttery,ANZSBT - An update on emerging infectious threats
http://files.interact.technology/J000523/Abstracts/167_Thornton.pdf,Abstract 167,Immunohaematology case studies - Interactive!,Meeting Room 219,Nicole Thornton,"ANZSBT Masterclass: Transfusion case studies, troubleshooting in immunohaematology lab (Nicole Thornton )"
http://files.interact.technology/J000523/Abstracts/168_Luban.pdf,Abstract 168,Paediatric transfusion cases or clinical problems,Meeting Room 214,Naomi Luban,"ANZSBT Masterclass: Paediatric transfusion cases or clinical problems (Naomi Luban)

"
http://files.interact.technology/J000523/Abstracts/169_Cohen.pdf,Abstract 169,Panel discussion,Meeting Room 212 & 213,Michael Crennan,ANZSBT: Panel discussion on haemovigilance
http://files.interact.technology/J000523/Abstracts/170_Cormie.pdf,Abstract 170,Panel discussion,Meeting Room 212 & 213,Richard Charlewood,ANZSBT: Panel discussion on haemovigilance
http://files.interact.technology/J000523/Abstracts/171_Klarica.pdf,Abstract 171,Panel discussion,Meeting Room 212 & 213,Barbara Bell,ANZSBT: Panel discussion on haemovigilance
http://files.interact.technology/J000523/Abstracts/172_Gates.pdf,Abstract 172,Panel discussion on haemovigilance,Meeting Room 212 & 213,Alison Street,ANZSBT: Panel discussion on haemovigilance
http://files.interact.technology/J000523/Abstracts/173_Panek-Hudson.pdf,Abstract 173,Panel discussion on haemovigilance,Meeting Room 212 & 213,James Daly,ANZSBT: Panel discussion on haemovigilance
http://files.interact.technology/J000523/Abstracts/174_Joyce.pdf,Abstract 174,Panel Discussion,Meeting Room 212 & 213,Jane Cook,ANZSBT: Panel discussion on haemovigilance
http://files.interact.technology/J000523/Abstracts/175_Kurtin.pdf,Abstract 175,Comprehensive patient assessment: Rhetoric or reality?,Meeting Room 220,Emma Cohen,Nurses Symposium: Symptom management
http://files.interact.technology/J000523/Abstracts/176_Presta.pdf,Abstract 176,Exercise medicine,Meeting Room 220,Prue Cormie,Nurses Symposium: Symptom management
http://files.interact.technology/J000511/unavailable.pdf,Abstract 177,Positive Change for Life,Meeting Room 220,Daniela Klarica,Nurses Symposium: Symptom management
http://files.interact.technology/J000523/Abstracts/178_Trubiano.pdf,Abstract 178,Unmet needs of patients attending a Haematology Nurse-led Survivorship clinic,Meeting Room 220,Priscilla Gates,Nurses Symposium: Free Communication
http://files.interact.technology/J000523/Abstracts/179_Rowan.pdf,Abstract 179,Listening to our colleagues – Essential Primary care feedback on LTFU care plans,Meeting Room 220,Yvonne Panek-Hudson,Nurses Symposium: Free Communication
http://files.interact.technology/J000511/unavailable.pdf,Abstract 180,A novel approach in delivering vaccinations following an autologous stem cell transplant,Meeting Room 220,Trish Joyce,Nurses Symposium: Free Communication
http://files.interact.technology/J000523/Abstracts/181_Mineely.pdf,Abstract 181,Caregiver self-efficacy,Meeting Room 220,Sandra Kurtin,Nurses Symposium: Carer preparedness
http://files.interact.technology/J000523/Abstracts/182_Presta.pdf,Abstract 182,Development and implementation of a multidisciplinary (MD) support program for carers of patients undergoing allogeneic haematopoietic stem cell transplantation,Meeting Room 220,Maria Presta,Nurses Symposium: Carer preparedness
http://files.interact.technology/J000523/Abstracts/183_McCarthy.pdf,Abstract 183,Living the experience as a carer,Meeting Room 220,Marcella Iaconis,Nurses Symposium: Carer preparedness
http://files.interact.technology/J000523/Abstracts/184_Haywood.pdf,Abstract 184,Addressing antibiotic allergy in haematology patients - pathways to better prescribing,Meeting Room 220,Jason Trubiano,Nurses Symposium: Bugs and drugs
http://files.interact.technology/J000523/Abstracts/185_Kurtin.pdf,Abstract 185,Drug interactions with anti-infective agents in haematological malignancies,Meeting Room 220,Gail Rowan,Nurses Symposium: Bugs and drugs
http://files.interact.technology/J000523/Abstracts/186_Button.pdf,Abstract 186,Setting the scene - clinical scenario,Meeting Room 220,Andrew Roberts,Nurses Symposium: Case study discussion - Allografting a Jehovah's Witness patient with MDS
http://files.interact.technology/J000523/Abstracts/187_Abo.pdf,Abstract 187,Nursing considerations,Meeting Room 220,Siobhan Mineely,Nurses Symposium: Case study discussion - Allografting a Jehovah's Witness patient with MDS
http://files.interact.technology/J000523/Abstracts/188_Meijer%20%28nee%20Kenny%29.pdf,Abstract 188,Ethical implications of allografting a Jehovah Witness patient with MDS,Meeting Room 220,Maria Presta,Nurses Symposium: Case study discussion - Allografting a Jehovah's Witness patient with MDS
http://files.interact.technology/J000523/Abstracts/189_Levak.pdf,Abstract 189,Fulfilling the vision of youth-friendly cancer care: How well are we doing?,Meeting Room 220,Maria McCarthy,Nurses Symposium: Focus on AYA
http://files.interact.technology/J000523/Abstracts/190_Horne.pdf,Abstract 190,A practical review of the haematology nurse's role in the care of adolescent and young adults,Meeting Room 220,Peter Haywood,Nurses Symposium: Focus on AYA
http://files.interact.technology/J000523/Abstracts/191_Downs.pdf,Abstract 191,Safe delivery and management of new agents in multiple myeloma,Meeting Room 220,Sandra Kurtin,Nurses Masterclass: Safe delivery and management of new agents in multiple myeloma (Sandra Kurtin)
http://files.interact.technology/J000523/Abstracts/192_King.pdf,Abstract 192,Hope for the best yet prepare for the rest: A systematic review of advance care planning prior to stem cell transplantation,Meeting Room 220,Elise Button,Nurses Symposium: Free Communication
http://files.interact.technology/J000523/Abstracts/193_Steele.pdf,Abstract 193,Hospital and home based exercise program following Allogeneic Haematopoietic Stem Cell Transplantation,Meeting Room 220,Shaza Abo,Nurses Symposium: Free Communication
http://files.interact.technology/J000523/Abstracts/194_Krishna.pdf,Abstract 194,Miss A’s treatment journey through a double cord stem cell transplant ; The importance of palliative care input in stem cell transplant patients care; A case study presentation,Meeting Room 220,Natalie Meijer (nee Kenny),Nurses Symposium: Free Communication
http://files.interact.technology/J000523/Abstracts/195_Vassili.pdf,Abstract 195,Changing indications for autologous HSCT at St Vincent's Hospital and the impact of severe auto-immune conditions such as Multiple Sclerosis and Scleroderma at the general ward level,Meeting Room 220,Serafina Levak,Nurses Symposium: Free Communication
http://files.interact.technology/J000523/Abstracts/196_Wall.pdf,Abstract 196,Autologous stem cell transplant In patients with cardiac AL amyloidosis post an orthotopic heart transplant: a case study,Meeting Room 220,Annabel Horne,Nurses Symposium: Free Communication
http://files.interact.technology/J000523/Abstracts/197_Botti.pdf,Abstract 197,A collaborative approach in the management of late onset grade IV skin GVHD of an adolescent male post allogenic bone marrow transplant,Meeting Room 220,Erin Downs,Nurses Symposium: Free Communication
http://files.interact.technology/J000523/Abstracts/198_Hart.pdf,Abstract 198,"myeNURSE: working together to improve outcomes for those with myeloma, a focus on best practice and information sharing",Meeting Room 220,Tracy King,Nurses Symposium: Free Communication
http://files.interact.technology/J000523/Abstracts/199_Hill.pdf,Abstract 199,Trial of the use of methoxyflurane inhalation for analgesic control during bone marrow biopsy in a Haematology Outpatient Department,Meeting Room 220,Andrew Steele,Nurses Symposium: Free Communication
http://files.interact.technology/J000523/Abstracts/200_Elwood.pdf,Abstract 200,Facilitating effective transition from secondary to primary care: Trial of a new nurse-led model for haematology patients post cancer treatment discharge,Meeting Room 220,Anne Krishna,Nurses Symposium: Free Communication
http://files.interact.technology/J000523/Abstracts/201_Crompton.pdf,Abstract 201,Understanding MPNs,Meeting Room 220,Catherine Vassili,Nurses How To - Understanding MPNs
http://files.interact.technology/J000523/Abstracts/202_Pepe.pdf,Abstract 202,Understanding cytogenetics,Meeting Room 217,Meaghan Wall,Nurses How To - session 2
http://files.interact.technology/J000523/Abstracts/203_Fleming.pdf,Abstract 203,Developing a robust clinical audit: How to get from your idea to presentation/publication,Meeting Room 218,Mari Botti,Nurses How To - session 3
http://files.interact.technology/J000523/Abstracts/204_Watson.pdf,Abstract 204,Allograft donor selection,Meeting Room 220,Cathie Hart,Nurses Symposium: Focus on Transplant/Apheresis
http://files.interact.technology/J000523/Abstracts/205_Tong.pdf,Abstract 205,Apheresis case study: What to do when you’re not U,Meeting Room 220,Aaron Hill,Nurses Symposium: Focus on Transplant/Apheresis
http://files.interact.technology/J000523/Abstracts/206_Palladinetti.pdf,Abstract 206,Establishment of an Australian cord blood-derived iPSC bank for clinical use,Meeting Room 211,Ngaire Elwood,BMTSAA Symposium: Novel cellular therapies
http://files.interact.technology/J000523/Abstracts/207_Chiappini.pdf,Abstract 207,How could cord blood help children with cerebral palsy?,Meeting Room 211,Kylie Crompton,BMTSAA Symposium: Novel cellular therapies
http://files.interact.technology/J000523/Abstracts/208_Trickett.pdf,Abstract 208,Cord blood adjunct therapy in cardiopulmonary-bypass surgery for congenital heart diseases,Meeting Room 211,Salvatore Pepe,BMTSAA Symposium: Novel cellular therapies
http://files.interact.technology/J000523/Abstracts/209_Hill.pdf,Abstract 209,Immunotherapy in acute lymphoblastic leukaemia,Meeting Room 211,Shaun Fleming,BMTSAA Symposium: Immunotherapies
http://files.interact.technology/J000523/unavailable.pdf,Abstract 210,Initial comparison of 3 apheresis platforms for supporting the collection of CD3+ cells for CAR-T production,Meeting Room 211,Doug Watson,BMTSAA Symposium: Immunotherapies
http://files.interact.technology/J000511/unavailable.pdf,Abstract 211,Pre-apheresis T cell counts can be used to calculate additional blood volume to be processed for donor lymphocyte cryopreservation,Meeting Room 211,Daochen Tong,BMTSAA Symposium: Free Communications: 'Cases from the bench'
http://files.interact.technology/J000511/unavailable.pdf,Abstract 212,Inter-laboratory Comparison of Viable CD34+ in Aliquots of Cryopreserved HPC,Meeting Room 211,Patricia Palladinetti,BMTSAA Symposium: Free Communications: 'Cases from the bench'
http://files.interact.technology/J000511/unavailable.pdf,Abstract 213,"Sepax II vs Spectra Optia, a comparison of two technologies for red blood cell depletion",Meeting Room 211,Paul Chiappini,BMTSAA Symposium: Free Communications: 'Cases from the bench'
http://files.interact.technology/J000511/unavailable.pdf,Abstract 214,"Thaw, Wash and Infusion of Unrelated Donor HPC, Cord Blood",Meeting Room 211,Annette Trickett,BMTSAA Symposium: Free Communications: 'Cases from the bench'
http://files.interact.technology/J000511/unavailable.pdf,Abstract 215,BMTL Pathwest: from concept to production,Meeting Room 211,Celeste Hill,BMTSAA Symposium: Free Communications: 'Cases from the bench'